At the beginning of the pandemic, remote retinal imaging declined sharply due to a recommendation to stop nonessential eye care services in the first months of 2020, said Parisa Emami-Naeni, MD, MPH, assistant professor of ophthalmology at University of California, Davis, and vitreoretinal surgeon and uveitis specialist at UC Davis Eye Center.
At the beginning of the pandemic, remote retinal imaging declined sharply due to a recommendation to stop nonessential eye care services in the first months of 2020, said Parisa Emami-Naeni, MD, MPH, assistant professor of ophthalmology at University of California, Davis, and vitreoretinal surgeon and uveitis specialist at UC Davis Eye Center.
Transcript
Use of remote retinal imaging initially declined sharply during the first months of the pandemic in 2020. What do you attribute this initial decline to when adoption of virtual or video visits increased overall in the early months of the pandemic?
So, in our study, we looked at the administrative claims data on individuals with private insurance or Medicare Advantage plans between early 2020—January 2020—until the end of 2020. And, as you mentioned, we found that the use of remote eye imaging declined sharply at the beginning of the pandemic—in the months of March and April 2020—with about a 60% decline in the number of the insurance claims for teleophthalmology.
However, in the latter half of 2020, the incidence of the claims increased back to the prepandemic levels. We think that the initial decline is most likely related to the initial period of the COVID-19 lockdowns and the American Academy of Ophthalmology recommendations to stop nonessential eye care services at that time. Also, the uncertainty of the situation at the beginning of the pandemic was likely contributing to this.
Changes that were made to reimbursements of televisits and teleophthalmology by [CMS] later on encouraged the use of these services later in the year. So, the numbers went back up.
NGS-Based Test Accurately Detects Post–Allo-HSCT Relapse in AML, MDS
February 21st 2025The next-generation sequencing (NGS)–based AlloHeme test accurately predicted relapse following allogeneic hematopoietic stem cell transplantation (allo-HSCT) in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).
Read More
Prostate Cancer Studies Show Why Personalized Treatment, Trial Diversity Matter, Dorff Says
February 21st 2025Tanya B. Dorff, MD, medical oncologist and professor in City of Hope’s Department of Medical Oncology & Therapeutics Research, was a discussant for the TALAPRO-2 and STOPCAP trials at the opening session of ASCO GU.
Read More
Politics vs Science: The Future of US Public Health
February 4th 2025On this episode of Managed Care Cast, we speak with Perry N. Halkitis, PhD, MS, MPH, dean of the Rutgers School of Public Health, on the public health implications of the US withdrawal from the World Health Organization and the role of public health leaders in advocating for science and health.
Listen
5 Key Health Care Moments During President Trump's First Month Back in Office
February 21st 2025President Donald J. Trump pushed for significant health care changes during his first month back in office, through executive orders affecting managed care, drug pricing, and clinical trial diversity guidance.
Read More